



## Correction to: A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females

Yang Xu<sup>1</sup> · Kristin Gabriel<sup>1</sup> · Yi Wang<sup>1</sup> · Yanchen Zhou<sup>2</sup> · Osaro Eisele<sup>1</sup> · Apinya Vutikullird<sup>3</sup> · Daniel D. Mikol<sup>1</sup> · Edward Lee<sup>1</sup>

Published online: 6 May 2019  
© Springer Nature Switzerland AG 2019

**Correction to: CNS Drugs**  
<https://doi.org/10.1007/s40263-019-00626-2>

An Online First version of this article was made available online at <http://link.springer.com/journal/40263/onlineFirst/page/1> on 8 April 2019. An error was subsequently identified in the article, and the following correction should be noted:

Section 2.3 (Trial Design), sentence 2- the text that read:

During the study, subjects received three 28-day cycles of daily combined oral contraceptive (21 days of

ethinylestradiol 0.025 mg/norgestimate 0.25 mg followed by inert ingredients for 7 days) (Fig. 1).

Should read:

During the study, subjects received three 28-day cycles of daily combined oral contraceptive (21 days of ethinylestradiol 0.035 mg/norgestimate 0.25 mg followed by inert ingredients for 7 days) (Fig. 1).

---

The original article can be found online at <https://doi.org/10.1007/s40263-019-00626-2>.

---

✉ Yang Xu  
yangx@amgen.com

<sup>1</sup> Amgen Inc, 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA

<sup>2</sup> Amgen Inc, 1120 Veterans Blvd, South San Francisco 94080, CA, USA

<sup>3</sup> WCCT Global, Cypress, CA, USA